At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 643 enrolled
Drug / intervention
COR388 capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
In Brief
A Phase 3 clinical trial evaluating COR388 capsule and Placebo capsule for Alzheimer Disease. Completed, enrolled 643 participants across 93 sites in 6 countries.
Detailed Summary
This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD) dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesFrance, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartMar 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedJan 30, 2019
Enrollment StartMar 28, 2019
Primary CompletionJan 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.4 years ago
Interventions
COR388 capsuledrug
BID (twice daily)
Placebo capsuledrug
BID